A
Angelina Collins
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
Jun 9, 2026
Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease
1:23
1:33
1:44
1:55

Angelina CollinsGUEST
who was the patient population in this study? So the patient population included those with defined as moderate to severely active Crohn's disease.

Angelina CollinsGUEST
They had to have both symptomatic disease activity and symptoms, but they also had to have endoscopically active disease on a centrally red scale.

Angelina CollinsGUEST
And so what that means is that the local provider videoed the scope and then sent it to a blinded gastroenterologist to grade it and determine disease activity.

Angelina CollinsGUEST
So in this way, all patients had both symptomatic disease activity and they also had endoscopy disease activity as well.
5 MINS LATER
